Andreas Krebs Buys Shares of Definium Therapeutics, Inc. $DFTX
Key Points
- Andreas Krebs bought 19,188 shares of Definium Therapeutics, Inc. ($DFTX).
- $DFTX last traded around $24.75.
Andreas Krebs, insider at Definium Therapeutics, Inc. ($DFTX), bought 19,188 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Definium Therapeutics, Inc. ($DFTX) Stock
Definium Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.